Sign Up

Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ

MELBOURNE, Australia, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that it closed an underwritten public offering of 1,000,000 shares of its common stock, par value $0.001 per share, at a price of $4.00 per share. The shares of common stock commenced trading on the Nasdaq Capital Market on August 15, 2025, under the ticker symbol, "PPCB".

The Company received aggregate gross proceeds of $4 Million from the offering, before deducting underwriting discounts and other related expenses. In addition, the Company has also granted the underwriter a 45-day option to purchase up to 150,000 additional shares of common stock at the public offering price, less underwriting discounts. The closing for the initial public offering occurred on August 18, 2025.

D. Boral Capital LLC and Craft Capital Management LLC acted as the book running managers for the offering.

Brunson Chandler & Jones PLLC, Salt Lake City, Utah, acted as counsel to the Company, and Sichenzia Ross Ference Carmel LLP, New York, NY, acted as counsel to the underwriters in connection with the offering.

A registration statement on Form S-1 relating to these securities was declared effective by the U.S. Securities and Exchange ...